Oruka Therapeutics, Inc.
ORKA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000907654
In the last 90 days, Oruka Therapeutics, Inc. insiders filed 0 open-market purchases and 14 sales; 255 institutions reported holding it in 13F filings for Q2 2026, worth $7.05B in total; Viking Global Investors is the only superinvestor holding it.
Q3 2021 vs. Q2 2021
How the institutions holding Oruka Therapeutics, Inc. changed between Q2 2021 and Q3 2021.
All holders in Q3 2021All holders in Q2 2021
| Measure | Q2 2021 | Q3 2021 | Change |
|---|---|---|---|
| Holders | 17 | 19 | +2 |
| Shares | 1.19M | 1.53M | +335.0K (+28.1%) |
| Value | $4.16M | $4.53M | +$361.0K (+8.7%) |
New holders (6)
Institutions that held Oruka Therapeutics, Inc. at the end of Q3 2021 but not at the end of Q2 2021.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Alpine Global Management, LLC | 16,715 | $49.0K | 0.01% |
| Millennium Management LLC | 15,874 | $47.0K | 0.00% |
| Minerva Advisors LLC | 10,000 | $30.0K | 0.02% |
| Simplex Trading, LLC | 1,270 | $4.00K | 0.00% |
| Parallel Advisors, LLC | 244 | $1.00K | 0.00% |
| Morgan Stanley | 17 | $0 | 0.00% |
Sold out (4)
Institutions that held Oruka Therapeutics, Inc. at the end of Q2 2021 and filed for Q3 2021 without it.
| Institution | Shares, Q2 2021 | Value, Q2 2021 |
|---|---|---|
| Goldman Sachs Group Inc | 13,918 | $49.0K |
| XTX Topco Ltd | 10,846 | $38.0K |
| UBS Group AG | 5,365 | $19.0K |
| JPMorgan Chase & Co | 133 | $0 |